The hot TNF inhibitor market with Humira, ‘King of Indication’

Humira has made a series of movements to expand its indications to secure the 1^st place.

According to the current industry concerned, as the Abbvie’s ‘Humira(Adalimumab)’ added two more indications recently, it is now approved incredibly for indications of 11 diseases. 

Considering the Janssen’s ‘Remicade(infliximab)’ with 7 indications and the Pfizer’s ‘Enbrel(etanercept)’ with 6 indications...